Company InflaRx N.V.

Equities

IFRX

NL0012661870

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

Sales per region

Ratings for InflaRx N.V.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
1.35 ^USD	+7.14%		-10.00%	-17.18%

Mar. 21	Transcript : InflaRx N.V. - Special Call
Mar. 21	InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

Number of employees: 62

USD in Million	2022	Weight	2023	Weight	Delta
Monoclonal Antibodies 100.0 %	0	nan %	0	100.0 %	-

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	nan %	0	100.0 %	-

Managers	Title	Age	Since
Renfeng Guo FOU	Founder	53	07-11-30
Niels Riedemann FOU	Founder	51	07-11-30
Thomas Taapken DFI	Director of Finance/CFO	59	20-09-30
Camilla Chong CTO	Chief Tech/Sci/R&D Officer	58	23-06-30
Daniel Vetter CTO	Chief Tech/Sci/R&D Officer	-	22-06-30
Maria Habel CTO	Chief Tech/Sci/R&D Officer	41	07-12-31
Bruce P. Burnett CTO	Chief Tech/Sci/R&D Officer	-	19-12-31
Jan Medina IRC	Investor Relations Contact	-	Feb. 21
Nicole Bertsch HRO	Human Resources Officer	-	21-02-28
Christian Schmid LAW	General Counsel	-	20-12-31

Members of the board	Title	Age	Since
Nicolas Fulpius FOU	Founder	51	07-11-30
Niels Riedemann FOU	Founder	51	07-11-30
Renfeng Guo FOU	Founder	53	07-11-30
Hege Hellstrom BRD	Director/Board Member	59	23-03-31
Richard Brudnick BRD	Director/Board Member	67	19-02-13
Anthony Gibney BRD	Director/Board Member	53	18-02-05
Mark Kubler BRD	Director/Board Member	49	14-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	58,883,272	54,560,784 ( 92.66 %)	0	92.66 %

Name	Equities	%	Valuation
STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD. 9.738 %	5,733,910	9.738 %	9 M $
Suvretta Capital Management LLC 9.738 %	5,733,910	9.738 %	9 M $
Point72 Asset Management LP 3.748 %	2,206,893	3.748 %	3 M $
Tang Capital Management LLC 3.182 %	1,873,753	3.182 %	3 M $
Renfeng Guo 2.993 %	1,762,144	2.993 %	3 M $
Eversept Partners LP 2.216 %	1,305,140	2.216 %	2 M $
Citigroup Global Markets, Inc. (Investment Management) 2.040 %	1,201,301	2.040 %	2 M $
Niels Riedemann 1.815 %	1,068,908	1.815 %	2 M $
Mark Kuebler 1.630 %	960,015	1.630 %	1 M $
Morgan Stanley Capital Services LLC 1.567 %	922,821	1.567 %	1 M $

InflaRx NV

Winzerlaer Strasse 2

07745, Jena

http://www.inflarx.de

Name	Category and Sector
InflaRx GmbH InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany.	Biotechnology

Name

Category and Sector

Biotechnology

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.266 EUR

Average target price

7.372 EUR

Spread / Average Target

+482.50%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
INFLARX N.V.	-17.18%	79.49M
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.37B
ARGENX SE	-1.80%	21.37B
BIONTECH SE	-17.75%	20.92B
GENMAB A/S	-6.91%	18.64B
WUXI APPTEC CO., LTD.	-42.00%	16.4B
BEIGENE, LTD.	-28.19%	13.53B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.28B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.85B

Bio Therapeutic Drugs